Literature DB >> 17009974

Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma.

D Ripley1, R Tunuguntla, L Susi, N Chegini.   

Abstract

The objective of this study was to determine the spatial expression of matrix metalloproteinases (MMPs) and their physiologic inhibitors, the tissue inhibitor of MMP (TIMP)-3 and TIMP-4, in ovarian carcinoma compared to normal ovaries. Immunohistochemistry was carried out in this study. Tissue sections prepared from normal ovarian tissues from throughout the menstrual cycle (N = 20) and ovarian carcinomas (N = 45) characterized as stage I (N = 5), stage III/IV (N = 40) were immunostained using polyclonal antibodies to the latent and the active form of MMP-26, TIMP-3, and a monoclonal antibody to TIMP-4. Immunoreactive MMP-26, TIMP-3, and TIMP-4 were detected in all the ovarian cell types in normal and tumor tissues. In normal ovarian tissues, theca externa and luteal cells immunostained with high intensity for MMP-26 and TIMPs while theca/granulosa cell staining intensity increased as lutenization progressed. There was low immunostaining of the ovarian stromal and surface epithelial cells for MMP-26, with moderate staining for TIMPs. In the carcinoma specimens, cancer cells and vascular endothelial cells displayed the highest staining intensity compared to adjacent nontumor areas. The immunostaining intensity of MMP-26 and TIMP-3 increased with stage of tumor with the invading tumor cells displaying the strongest immunostaining. MMP-26, TIMP-3, and TIMP-4 are expressed in normal ovarian as well as ovarian tumors with elevated expression in the invasive tumor cells suggesting a potential role for MMP-26 in normal ovary and ovarian cancer biologic function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009974     DOI: 10.1111/j.1525-1438.2006.00714.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  9 in total

1.  Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients.

Authors:  Qinglin Hu; Chuanjing Yan; Chengfei Xu; Hai Yan; Lian Qing; Yanjun Pu; Zeyou He; Xiaojun Li
Journal:  Tumour Biol       Date:  2013-12-08

2.  Ovarian expression, localization, and function of tissue inhibitor of metalloproteinase 3 (TIMP3) during the periovulatory period of the human menstrual cycle.

Authors:  Katherine L Rosewell; Feixue Li; Muraly Puttabyatappa; James W Akin; Mats Brännström; Thomas E Curry
Journal:  Biol Reprod       Date:  2013-11-21       Impact factor: 4.285

Review 3.  Ovarian cancer: involvement of the matrix metalloproteinases.

Authors:  Linah Al-Alem; Thomas E Curry
Journal:  Reproduction       Date:  2015-04-27       Impact factor: 3.906

4.  In-depth LC-MS/MS analysis of the chicken ovarian cancer proteome reveals conserved and novel differentially regulated proteins in humans.

Authors:  Angelito I Nepomuceno; Huanjie Shao; Kai Jing; Yibao Ma; James N Petitte; Michael O Idowu; David C Muddiman; Xianjun Fang; Adam M Hawkridge
Journal:  Anal Bioanal Chem       Date:  2015-07-10       Impact factor: 4.142

5.  Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines.

Authors:  Andrea Schröpfer; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Sonja Feix; Jelena Anacker
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

Review 6.  Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.

Authors:  Maria V Barbolina; Rebecca J Burkhalter; M Sharon Stack
Journal:  Biochem J       Date:  2011-07-01       Impact factor: 3.857

7.  Identification of five serum protein markers for detection of ovarian cancer by antibody arrays.

Authors:  Weidong Jiang; Ruochun Huang; Chaohui Duan; Liwu Fu; Yun Xi; Yuebo Yang; Wei-Min Yang; Dongzi Yang; Dong-Hua Yang; Ruo-Pan Huang
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

8.  DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer.

Authors:  Jieyu Wang; Jun Li; Ruifang Chen; Huiran Yue; Wenzhi Li; Beibei Wu; Yang Bai; Guohua Zhu; Xin Lu
Journal:  Clin Epigenetics       Date:  2021-10-13       Impact factor: 6.551

Review 9.  Tissue inhibitor of metalloproteinases-4. The road less traveled.

Authors:  Jorge Melendez-Zajgla; Luis Del Pozo; Gisela Ceballos; Vilma Maldonado
Journal:  Mol Cancer       Date:  2008-11-21       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.